Angela Sardaro | Immunotherapy | Excellence in Research

Published on by Top Pharmaceutical

Angela Sardaro | Immunotherapy | Excellence in Research

Assoc. Prof. Dr. Angela Sardaro at ASL Lecce, Italy.

Assoc. Prof. Dr. Angela Sardaro is a distinguished Italian academic and medical professional specializing in Radiotherapy and Diagnostic Imaging. She has served as a professor at the University of Bari Aldo Moro, coordinating degree programs and teaching across multiple disciplines, including Radiology, Oncology, and Medical Imaging. With over 15 years of academic experience, she has guided numerous theses and led scientific seminars. Dr. Sardaro’s prolific research output includes 81 indexed publications, an h-index of 15, and 842 citations šŸ“ˆ. Her contributions extend globally, with collaborations in the UK and Italy, reinforcing her impact in oncology and radiological science.

Publication ProfileĀ 

scopus

Education

Assoc. Prof. Dr. Angela Sardaro has demonstrated outstanding commitment to medical education šŸ‘©ā€āš•ļøšŸ“š, coordinating the Degree Course in Radiologic Imaging and Radiotherapy Techniques at the University of Bari Aldo Moro šŸŽ“. With over 15 years of teaching experience across various undergraduate and postgraduate programs, she has taught core disciplines like Radiotherapy, Radiobiology, and Diagnostic Imaging šŸ§¬šŸ”¬. Her academic service spans doctoral programs, masterā€™s training in pain therapy, and prestigious collaborations with institutions in Florence and the UK šŸ‡®šŸ‡¹šŸ‡¬šŸ‡§. Dr. Sardaro has delivered 1,440 hours of lectures and 4,160 hours of professional training šŸ“Š, shaping future generations in radiological sciences.

Experience

Assoc. Prof. Dr. Angela Sardaro has made a remarkable impact on clinical education and hands-on training in radiological sciences šŸ‘©ā€āš•ļøšŸ§². She has guided radiologic technologists, medical students, and postgraduates through innovative programs that incorporate cutting-edge technologies like PET/CT, proton therapy, and radiogenomics šŸ’”šŸ§¬. Her dedication to advancing clinical competence is evident in the numerous experimental and clinical theses completed under her mentorship šŸ“–šŸŽ“. By blending theory with real-world application, she has nurtured a generation of professionals equipped to meet the evolving challenges of diagnostic imaging and radiation therapy.

Research FocusĀ 

Assoc. Prof. Dr. Angela Sardaroā€™s research focus lies at the intersection of oncologic radiotherapy, advanced diagnostic imaging, and radiation-induced toxicities šŸŽÆšŸ§². Her work spans critical areas such as hypofractionated radiotherapy, prostate cancer, head and neck squamous cell carcinoma, breast cancer survivorship, and radiogenomics šŸ“ŠšŸ§¬. She also investigates rare radiation-associated tumors like angiosarcomas, while leveraging cutting-edge tools like 18F-FCH PET/CT, MR imaging, and stereotactic radiosurgery šŸ§ šŸ”¬. Her systematic reviews and meta-analyses contribute to refining treatment protocols and improving patient outcomes šŸ©»šŸ‘©ā€āš•ļø. Dr. Sardaroā€™s impactful research bridges clinical innovation with evidence-based radiation oncology.

Publication Top Notes

  • Single-Dose Radiation Therapy for Localized Prostate Cancer: Where Does the Evidence Lead?
  • Nodal assessment and extranodal extension in head and neck squamous cell cancer: insights from computed tomography and magnetic resonance imaging
  • Evidences on the Use of Hypofractionation in Postoperative/Salvage Radiotherapy for Prostate Cancer: Systematic Review of the Literature and Recent Developments
  • Long-Term Breast Cancer Risk in Hodgkin Lymphoma Survivors: Evaluating Background Parenchymal Enhancement and Radiotherapy-Induced Toxicity
  • Radiation-Associated Angiosarcoma of the Breast: The State of the Art of a Rare and Aggressive Disease
  • Radiosurgery in Grade II and III Meningiomas: A Systematic Review and Meta-Analysis
  • Role of 18F-FCH PET/CT in Detecting Recurrences of Prostate Cancer After Curative Treatments

Sudeep Nagaraj | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Sudeep Nagaraj | Immunotherapy | Best Researcher Award

Dr. Sudeep Nagaraj, ICAR-NIVEDI, India

Dr. Sudeep Nagaraj is an accomplished molecular biologist and research scientist with a Ph.D. from GITAM University (2025) šŸŽ“. He possesses extensive hands-on expertise in molecular genetics, cytogenetics, proteomics, virology, and phytochemistry šŸ§ŖšŸŒæ. With over six years of academic and research experience, he has served in various prestigious institutions including ICAR-NIVEDI and ICAR-IVRI šŸ›ļø. Dr. Nagaraj has authored 20+ peer-reviewed publications on cytotoxicity, DNA barcoding, and viral epidemiology šŸ“š. His primary research focus lies in virology and molecular diagnostics, especially lumpy skin disease in livestock šŸ„šŸ¦ . He is known for blending academic rigor with applied research for public health impact šŸ’”.

Publication Profile

Google Scholar

Education

Dr. Sudeep Nagaraj holds a Ph.D. in Molecular Biology from GITAM University (2025) šŸ§¬, an MSc from SDUAHER, Tamaka Kolar (2016) šŸ§Ŗ, and a BSc from FGC, KGF (2012) šŸ“š. His academic journey began at Chinmaya Vidyalaya, Kolar (SSLC, 2007) and continued through BGS PU College (PUC, 2009) šŸ«. Professionally, he has accumulated diverse experience across esteemed research institutions and labs, contributing significantly to molecular and virology research šŸ§«. Additionally, he has one year of teaching experience in Molecular Biology at SIMS and RC, where he taught undergraduate students with dedication and clarity šŸŽ“šŸ§‘ā€šŸ«.

Experience

oDr. Sudeep Nagaraj has amassed rich experience through roles such as SRF at ICAR-NIVEDI (2021ā€“present) šŸ§¬, Young Professional-II at ICAR-IVRI (2020ā€“2021) šŸ§«, and Research Scientist at Cytogene Diagnostics (2019ā€“2020) šŸ”¬. His journey also includes positions at SIMS and RC, QTLomics, and IDBR. He taught Molecular Biology at SIMS and RC for a year at the UG level šŸŽ“. His hands-on skills span molecular genetics (PCR, DNA isolation, HRM), proteomics (SDS-PAGE, Bradford assay), cytogenetics (karyotyping), gene cloning, cell culture, virology (ELISA, virus titration), and phytochemistry (plant extract prep) šŸ§¬šŸŒæšŸ§«.

Awards

Dr. Sudeep Nagaraj has been honored with several prestigious awards for his outstanding contributions to scientific research and innovation šŸ§ šŸ”¬. He received the Young Scientist Award at the International Conference on Science, Health, and Engineering held in Chennai on January 11, 2020 šŸ†. In 2021, he was conferred the Best Researcher Award at the International Research Awards on New Science Inventions on August 11 in Chennai šŸ„‡. Most recently, in 2025, he was recognized once again with a Young Scientist Award from Scientific Laurels, celebrating his continued excellence in research šŸš€šŸ“š.

Research Focus

Dr. Sudeep Nagaraj’s research centers around molecular virology, cytogenetics, and immunology, with a significant emphasis on Lumpy Skin Disease (LSD) in livestock šŸ„. His work extends to plant-based cytotoxicity, DNA barcoding, and cell culture techniques, reflecting a strong interdisciplinary foundation šŸŒæšŸ§Ŗ. His studies explore pathogen-host interactions, viral evolution, and molecular diagnostics, contributing vital insights into disease spillovers and viral epidemiology across species šŸ§ šŸ”. He also focuses on PBMC assays, ELISA, and nanoparticle toxicity, bridging biomedicine, virology, and phytochemistry. His impactful contributions aid in zoonotic disease management and therapeutic development šŸ“ŠšŸ’‰šŸŒ¾.

Publication Top Notes

Lumpy Skin Disease (LSD) in Yak (Bos grunniens): An Evidence of Species Spillover from Cattle in India

Evaluation of In Vitro Cytotoxic Effects of Three Medicinal Plants on Peripheral Blood Mononuclear Cells (PBMC)

First evidence of lumpy skin disease in mithun (Bos frontalis) in India

An in vitro cytotoxic and genotoxic properties of Allamanda cathartica L. Latex green NPs on human peripheral blood mononuclear cells

Unravelling the genomic origins of lumpy skin disease virus in recent outbreaks

Evaluation of HCP5 and Chemokine C receptor type 5 gene polymorphisms in Indian psoriatic patients

DNA based identification of species of Zingiberaceae family plants using Bar-Hrm analysis

A SIMPLE, COSTĀ­EFFECTIVE, FAST AND EASY TO ISOLATE DNA PROTOCOL FROM HUMAN SAMPLES

Investigation of Comorbidity and Risk Analysis During Lumpy Skin Disease Outbreaks in India

Evaluation of invitro cytotoxic activity of parts of Murraya koenigii (curry) plant on human peripheral blood mononuclear cells

Separation and Optimisation of a Sucrose Density Gradient Centrifugation Protocol for Isolation of Peripheral Blood Mononuclear Cells (PBMC)

Fast and Easy Protocol of DNA Extraction from Fresh and Hard/Dried Plant Samples of Indian Spices

Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Published on by Top Pharmaceutical

Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Assist. Prof. Dr. Konstantinos Tsapakidis, University Hospital Of Larissa, Greece

Assist. Prof. Dr. Konstantinos Tsapakidis šŸŽ“šŸ‘Øā€āš•ļø is an esteemed Medical Oncologist at the University of Thessaly, Greece. With a Ph.D. focused on prostate cancer research, he holds European Certification in Medical Oncology šŸ…. Since 2018, he has been actively involved in clinical oncology, teaching postgraduate courses on cancer, diet, and immunotherapy šŸ½ļøšŸ§¬. Dr. Tsapakidis has authored numerous impactful publications šŸ“š, contributing significantly to cancer diagnostics and treatment. Passionate about education, he trains residents and nurses, advancing oncology knowledge. His expertise includes systemic antineoplastic therapies and immune-oncology šŸŒŸ.

Publication Profile

Orcid

Education

Assist. Prof. Dr. Konstantinos Tsapakidis šŸŽ“ is a dedicated Medical Oncologist with an impressive educational background. He earned his Biology degree from Aristotelian University of Thessaloniki šŸ§¬ (1998ā€“2002) and completed his Medicine degree at the University of Thessaly šŸ„ (2003ā€“2007). Dr. Tsapakidis achieved his Ph.D. with excellence (2005ā€“2012), researching prostate cancerā€™s cell-cycle and apoptosis mechanisms šŸ”¬. He specialized in Medical Oncology in 2017 šŸŽÆ and obtained the prestigious European Certification in Medical Oncology in 2018 šŸ…. He also enhanced his expertise through an Immune-Oncology e-learning program at the University of Piraeus in 2017ā€“2018 šŸ’».

Experience

Assist. Prof. Dr. Konstantinos Tsapakidis šŸ’¼ has extensive medical oncology experience. Since February 2025, he serves as Assistant Professor at the University of Thessaly šŸŽ“. From 2018 to 2025, he worked as Consultant in Medical Oncology at University Hospital of Larissa šŸ„. Previously, he was a University Scholar and Fellow Consultant there (2017ā€“2018) šŸ‘Øā€āš•ļø. He completed his residency in Medical Oncology (2014ā€“2017) and earlier trained in Internal Medicine and Hematology at Larissa hospitals šŸ©ŗ. Between 2008ā€“2009, he was a Scientific Associate in Medical Oncology, laying a strong foundation for his clinical career šŸ”¬.

Research Focus

Assist. Prof. Dr. Konstantinos Tsapakidisā€™s research focus lies primarily in Medical Oncology with a strong emphasis on cancer diagnosis, treatment, and immunotherapy. šŸ§¬šŸ©ŗ His work explores various cancer types including lung cancer, breast cancer, sarcomas, and rare cancers, investigating immunotherapy responses, molecular diagnostics, and tumor behavior. šŸ”¬šŸ’‰ He is particularly involved in studying biomarkers like PD-1/PD-L1, immune cell profiling, and novel therapeutic approaches to improve patient outcomes. šŸ§Ŗāš•ļø His research also covers cancer-associated complications like thrombosis and metastatic disease. Overall, his contributions advance personalized oncology care and innovative cancer treatment strategies.

Publication Top Notes

Pseudomyxoma Peritonei: A Challenging Clinical Diagnosis. Case Report and Review of the Literature

The Impact of Expert Pathology Review and Molecular Diagnostics on the Management of Sarcoma Patients: A Prospective Study of the Hellenic Group of Sarcomas and Rare Cancers

Pre-Existing Immunity Predicts Response to First-Line Immunotherapy in Non-Small Cell Lung Cancer Patients

ES-SCLC Patients with PD-L1+ CTCs and High Percentages of CD8+PD-1+T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment

Combinatorial analysis of CD4<SUP>+</SUP>Tregs and CD8<SUP>+</SUP>Teff to predict response to ICI in patients with ES-SCLC

Metachronous Single Pulmonary Metastasis of Prostate Cancer: Report of a Rare Case and Literature Review

SYNCHRONOUS DIAGNOSIS OF TESTICULAR AND THYROID CANCER IN A YOUNG MALE

A Proposed Nomogram Model for Recurrence of Non-Muscle Invasive Bladder Carcinoma COMMENT

Metastatic rectal cancer in the ampulla of Vater: A unique case

Radiotherapy and Breast Reconstruction: What Is the Ideal Timing? A Narrative Review

Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden

Efthalia Zervoudi | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Efthalia Zervoudi | Immunotherapy | Best Researcher Award

Dr. Efthalia Zervoudi, Hellenic Pasteur Institute, Greece

Dr. Efthalia Zervoudi is a senior researcher at the Hellenic Pasteur Institute with a PhD in Biochemistry from the University of Athens. Her research focuses on designing inhibitors targeting antigen-trimming aminopeptidases, contributing significantly to immunology and cancer biology. She has extensive experience in oncology and molecular biomarkers, having held positions at Cardiff University and University Hospital ā€œAttikon.ā€ Dr. Zervoudi has authored multiple influential publications and holds patents on aminopeptidase inhibitors. She has received prestigious fellowships, including the Welcome Trust ISSF fellowship, and continues to advance personalized medicine through innovative molecular diagnostic approaches.

Publication Profile

Google Scholar

Education

I completed my PhD in Biochemistry at the University of Athens (2012ā€“2016) with top honors, focusing on designing inhibitors targeting antigen-trimming aminopeptidases. Before that, I earned my Masterā€™s degree in Biochemistry from the same university (2010ā€“2012), studying the specificity pockets of aminopeptidases involved in antigen processing. My academic journey began with a Bachelorā€™s degree in Chemistry from the University of Patras (2003ā€“2008), where I researched proteoglycans in cancer patients under Prof. Dimitrios Vynios. šŸŽ“ Prior to university, I graduated high school with a strong average score of 18.5/20, marking the start of my scientific path.

Experience

Dr. Efthalia Zervoudi is currently serving as a Senior Researcher at the Hellenic Pasteur Institute (2024ā€“present), contributing to cutting-edge biomedical research. From 2019 to 2023, she was a Research Coordinator at the Oncology Unit of University Hospital ā€œAttikonā€ in Greece. šŸ„ Previously, she held a postdoctoral research position at Cardiff Universityā€™s School of Medicine (2016ā€“2019), specializing in Infection and Immunity. šŸ”¬ Between 2010 and 2015, she collaborated with the Protein Chemistry Lab at the National Centre for Scientific Research ā€œDEMOKRITOSā€, working on the project: ā€œRational design and development of inhibitors for targeting antigen-trimming aminopeptidases.ā€

Awards

Dr. Efthalia Zervoudi has received several prestigious fellowships and awards recognizing her impactful research. In 2020, she was awarded funding by the Hellenic Society of Oncology for her study on Endoplasmic Reticulum Associated Peptidases as tools to understand cancer. šŸ§Ŗ In 2015, she received the esteemed Wellcome Trust ISSF Fellowship at Cardiff University. šŸ‡¬šŸ‡§ Earlier, in Fall 2014, the Hellenic Academy of Athens honored her with the ā€œAxillea and Aikaterini Dionysopoulouā€ award for her groundbreaking work on rationally designed inhibitors enhancing antigen presentation and cytotoxic T-cell responses. šŸ”¬šŸŽ–ļø Her research continues to push scientific boundaries.

Research Focus

Dr. Efthalia Zervoudi is a leading researcher in immunology and molecular biology, with a focus on antigen processing, immune regulation, and aminopeptidase function. Her work explores how enzymes like ERAP1 and ERAP2 trim antigenic peptides for presentation by MHC class I molecules, enhancing cytotoxic T-cell responsesā€”a crucial process in cancer immunotherapy and autoimmune disease research. šŸ§¬ She also develops targeted inhibitors to modulate immune responses, contributing to vaccine design and tumor immunity. šŸ§Ŗ Her research bridges biochemistry, structural biology, and immuno-oncology, with potential applications in personalized medicine.

Publication Top Notes

Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses

Probing the S1 specificity pocket of the aminopeptidases that generate antigenic peptides

A common single nucleotide polymorphism in endoplasmic reticulum aminopeptidase 2 induces a specificity switch that leads to altered antigen processing

Optimized peptideā€“MHC multimer protocols for detection and isolation of autoimmune T-cells

A role for naturally occurring alleles of endoplasmic reticulum aminopeptidases in tumor immunity and cancer pre-disposition

Autoimmune disease-associated variants of extracellular endoplasmic reticulum aminopeptidase 1 induce altered innate immune responses by human immune cells

3, 4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties

Novel selective inhibitors of aminopeptidases that generate antigenic peptides

Dual molecular mechanisms govern escape at immunodominant HLA A2-restricted HIV epitope

A common SNP in ER aminopeptidase 2 induces a specificity switch that leads to altered antigen processing

HPV16Ā E6Ā Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway

Correction: Konstantopoulos et al. HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway. Viruses 2024, 16, 113

Prof. Peng SHI|Immunotherapy|Best Researcher Award

Published on by Top Pharmaceutical

Prof. Peng SHI-Immunotherapy-Best Researcher Award

Prof. Peng SHI atCity University of Hong ,Hong Kong

Author Profile

Orcid

Early Academic Pursuits šŸŽ“

Peng Shi’s academic journey began with a solid foundation in electrical engineering, earning a Bachelor of Engineering degree from Wuhan University, China, in 2002. His keen interest in blending engineering with biological systems led him to pursue advanced studies in biomedical engineering at Columbia University, USA, where he earned both an M.Phil. in 2006 and a Ph.D. in 2009. At Columbia, Dr. Shi honed his expertise in interdisciplinary research, laying the groundwork for his future contributions to translational neuro-engineering and bioelectronics.

Professional Endeavors šŸ‘Øā€šŸ«

Dr. Shi’s career reflects a trajectory of academic excellence and innovation. After completing his Ph.D., he served as a Postdoctoral Fellow at the Department of Electrical Engineering, Massachusetts Institute of Technology (MIT), USA (2010ā€“2011), where he worked alongside leading researchers to advance the frontiers of bioelectronics and synthetic biology.

In 2011, Dr. Shi joined the Department of Biomedical Engineering at the City University of Hong Kong as an Assistant Professor. His dedication and groundbreaking work earned him an early promotion to Associate Professor (with tenure) in 2016 and subsequently to Full Professor in 2020. Notably, these advancements highlight his exceptional contributions to his field within a remarkably short timeframe.

Contributions and Research Focus šŸ”¬

Dr. Shi is a pioneer at the intersection of neuroscience and engineering, leveraging cutting-edge methodologies like nano-/micro-fabrication, bioelectronics, synthetic biology, high-resolution microscopy, and artificial intelligence. His research addresses critical challenges in translational neuro-engineering, emphasizing the development of high-throughput technologies and bioelectronic platforms to create innovative therapeutic systems.

His prolific output includes more than 90 publications in prestigious journals such as Nature Reviews Materials, Nature Biomedical Engineering, PNAS, Science Advances, and Advanced Materials. These works underscore his influence in fields spanning materials science, bioengineering, and neurotechnology. Beyond academic publishing, Dr. Shi has filed 18 patents, with several granted in the US and China. Some of these patents have served as the technological foundation for two biotech spin-offs, ANRim Biotechnology Limited and Electro-Ohmics, exemplifying the translational impact of his research.

Accolades and Recognition šŸ…

Dr. Shi’s excellence in research and innovation has been recognized with numerous prestigious awards and appointments:

  • 2015: Awarded the 1000 Young Talent Program by the National Natural Science Foundation of China (NSFC), a testament to his exceptional potential in scientific leadership.
  • 2018: Received the Special Recognition for Young Scholars from the World Cultural Council for his contributions to advancing global scientific understanding.
  • 2022: Appointed as Associate Editor of Brain Research (Elsevier), reflecting his influence in shaping the field of neuroscience.
  • 2023: Selected for the Biology and Medicine Panel of the Hong Kong RGC Joint Research Schemes, recognizing his leadership in biomedical research.

Dr. Shi has also delivered over 100 invited talks at global conferences, workshops, and academic institutions, further solidifying his reputation as a thought leader.

Impact and Influence šŸŒ

Dr. Shi’s innovations have a far-reaching impact, bridging the gap between basic research and clinical applications. His high-throughput bioelectronic platforms are revolutionizing therapeutic strategies, particularly in the realm of neuro-engineering. The biotech companies he co-founded, such as ANRim Biotechnology Limited, have secured significant funding, including RMB15M in angel investments, and are valued at HKD70M, demonstrating his success in translating academic research into viable commercial solutions.

As a grant referee for organizations like the NSFC, European Research Council, and Hong Kong UGC, Dr. Shi contributes to shaping the global research landscape. His expertise is further acknowledged through his role as a manuscript reviewer for leading publishers such as Nature, Wiley, and Elsevier.

Legacy and Future Contributions šŸŒŸ

Dr. Peng Shi’s work is paving the way for the next generation of therapeutic technologies and bioelectronic systems. By fostering interdisciplinary collaborations and mentoring emerging scholars, he is shaping the future of biomedical engineering. His patents and spin-offs ensure that his innovations continue to benefit society, bridging the divide between academia and industry.

Looking forward, Dr. Shi is poised to expand his influence through groundbreaking discoveries in synthetic biology, neuro-engineering, and artificial intelligence, driving advancements in healthcare and enhancing human well-being. His legacy will undoubtedly inspire future researchers and innovators, cementing his status as a transformative figure in biomedical engineering.

Notable Publication

Multifunctional Hydrogel Electronics for Closed-loop Antiepileptic Treatment

  • AuthorsĀ  Ā :Yuan WANG;Ā Guangyu ZHU;Ā Shu Chen;Ā Chenjie Xu;Ā Kai Xie;Ā Jin Qu;Ā Peng SHI;Ā xingdao he
  • JournalĀ  Ā  : Science Advances
  • YearĀ  Ā  Ā  Ā  Ā :2024

Few-shot meta-learning applied to whole brain activity maps improves systems neuropharmacology and drug discovery

      • AuthorsĀ  Ā : Xuan Luo;Ā Yanyun Ding;Ā Yi Cao;Ā Zhen LIU;Ā Wenchong Zhang;Ā Shangzhi Zeng;Ā Shuk Han Cheng;Ā Honglin Li;Ā Stephen J
      • JournalĀ  Ā  : iScience
      • YearĀ  Ā  Ā  Ā  Ā :2024

Integrated Piezoelectric Vascular Graft for Continuous Real-Time Hemodynamics Monitoring

  • AuthorsĀ  Ā : Zhiqiang Ma;Ā Weibin Jia;Ā Jing ZHANG;Ā xingdao he;Ā Shiyuan Liu;Ā Mohamed Elhousseini Hilal;Ā Xiang ZHOU
  • JournalĀ  Ā  : Functional Materials
  • YearĀ  Ā  Ā  Ā  Ā :2024

Nanopores-templated CNT/PDMS Microcolumn Substrate for the Fabrication of Wearable Triboelectric Nanogenerator Sensors to Monitor Human Pulse and Blood Pressure

  • AuthorsĀ  Ā :Tao Zhang;Ā Chuanjie Yao;Ā Xingyuan Xu;Ā Zhibo Liu;Ā Zhengjie Liu;Ā Tiancheng Sun;Ā Shuang Huang.
  • JournalĀ  Ā  Ā : Materials Technologies
  • YearĀ  Ā  Ā  Ā  Ā :2024Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā  Ā Ā 

Deciphering the Temporalā€“Spatial Interactive Heterogeneity of Long Non-Coding RNAs and RNA-Binding Proteins in Living Cells at Single-Cell Resolution

  • AuthorsĀ  Ā : Deyuan Yang;Ā Cheng Li;Ā Yutong Kong;Ā Yian Pei;Ā Bing Miao;Ā Gaole Dai;Ā Pi Ding;Ā Peng Shi;Ā Zixun
  • JournalĀ  Ā  Ā : American Chemical Society
  • YearĀ  Ā  Ā  Ā  Ā :2024Ā  Ā  Ā  Ā  Ā Ā 

Dr. Annie Zhang|Immunotherapy|Best Researcher Award

Published on by Top Pharmaceutical

Dr. Annie Zhang|Immunotherapy|Best Researcher Award

Dr. Annie Zhang at Cambridge,United States

PROFILEĀ Ā 

 

Scopus

Dr. Annie Zhang embarked on her academic journey with a strong foundation in medicine and public health, earning an MD and an MPH. Her dual degrees equipped her with a nuanced understanding of clinical medicine and the critical public health frameworks essential for managing and preventing diseases at both population and individual levels. Driven by a commitment to advancing therapeutic options and improving patient outcomes, she honed her knowledge in both biostatistics and epidemiology. These skills have been foundational throughout her career, particularly in her roles focused on evidence generation and clinical research.

šŸŒŸ Professional Endeavors

Throughout her distinguished career, Dr. Zhang has held senior roles at prominent pharmaceutical companies, demonstrating her expertise in medical affairs, clinical research, and strategic evidence generation.

  1. Sanofi, Cambridge, MA
    As the Global Senior Medical Director in Immunology & Dermatology since 2018, Dr. Zhang has led impactful initiatives in Medical Evidence Generation within Global Medical Affairs. Her key achievements include winning Sanofiā€™s ā€œBest of Bestā€ award in 2023 and receiving a 1st Place Poster award at the American Academy of Dermatology (AAD) conference in 2024 for her workā€™s scientific importance. Her leadership has propelled Sanofiā€™s immunology initiatives, particularly through studies such as PEDISTAD and INFANTSTAD, which focus on disease modification and prevention of the atopic march.
  2. Apellis, Waltham, MA
    In her tenure as Medical Director at Apellis from January 2017 to December 2017, Dr. Zhang was responsible for strategic planning and clinical development in hematology, overseeing Phase II and III studies in conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA). Her role included extensive interaction with thought leaders and the clinical team to design and optimize trial strategies.
  3. Biogen, Cambridge, MA
    From 2009 to 2016, Dr. Zhang held several pivotal roles at Biogen, advancing from Medical Director in Global Medical Affairs to leading biostatistical teams for key drug programs like Tecfidera. She worked on Tysabriā€™s lifecycle management, supporting clinical trial design, data generation, and publication strategies, especially in multiple sclerosis (MS). Her expertise in biostatistics and clinical research design strengthened Biogenā€™s data-driven approaches, particularly in Phase III and IV clinical trials.
  4. PAREXEL International, Lowell, MA
    Dr. Zhang worked as a Senior Biostatistician at PAREXEL from 2007 to 2009, leading biostatistical tasks across diverse therapeutic areas, including oncology, CNS disorders, and cardiovascular disease. Her meticulous approach ensured the quality and accuracy of statistical reports for clinical trials, contributing to numerous successful projects within the biostatistics team.
  5. New England Research Institutes, Watertown, MA
    Early in her career, Dr. Zhang served as an Associate Research Scientist at NERI from 2000 to 2007, where she conducted critical statistical analyses for clinical research, laying the groundwork for her later expertise in biostatistics and clinical study design.

šŸ’” Contributions and Research Focus

Dr. Zhangā€™s research has centered around dermatology, immunology, and hematology. At Sanofi, her work in immunology has led to groundbreaking insights on skin barrier integrity and neuroimmune function, providing essential evidence for the prevention of atopic march. She has also driven significant advancements in real-world evidence generation, particularly in cross-functional collaboration with global market access and regulatory teams, demonstrating her strategic alignment with organizational goals and patient needs.

šŸ† Accolades and Recognition

Dr. Zhangā€™s achievements have earned her numerous accolades, including the prestigious ā€œBest of Bestā€ award at Sanofi in 2023. In addition, she received 1st Place at the AAD 2024 Poster Award for her study on skin barrier health. Her work has also made her one of the most-read and cited authors in Allergy and Pediatric Dermatology in 2024, underscoring her impact and visibility in her field.

šŸŒ Impact and Influence

Through her extensive collaborations, Dr. Zhang has influenced clinical practices and regulatory frameworks worldwide. Her involvement in key study proposals and evidence generation initiatives has significantly impacted the medical communityā€™s understanding of dermatological conditions. Her efforts in strategic planning, data generation, and cross-functional teamwork have positioned her as an influential figure in dermatology and immunology, particularly in advancing therapies that meet rigorous safety and efficacy standards.

šŸŒ± Legacy and Future Contributions

Dr. Zhangā€™s legacy lies in her innovative approach to medical evidence generation and her unwavering commitment to patient-centered research. Her leadership in studies such as PEDISTAD and INFANTSTAD has set new standards for clinical research in dermatology and immunology. As she continues her work at Sanofi, Dr. Zhangā€™s contributions promise to expand the understanding and treatment of complex immunological conditions, impacting healthcare practices on a global scale.

Through her career, Dr. Zhang has exemplified excellence, dedication, and a strategic vision, ensuring her place as a respected leader in the pharmaceutical and clinical research sectors. Her ongoing work will undoubtedly continue to shape medical innovations and patient care improvements, leaving a lasting legacy in the fields of immunology and dermatology.

šŸŽ“PublicationĀ 

Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM

  • AuthorsĀ  Ā :Fox, R.J., Gold, R., Phillips, J.T., … Zhang, A., Marantz, J.L.
  • JournalĀ  Ā  :Neurology and Therapy
  • YearĀ  Ā  Ā  Ā  Ā :2017

Number Needed to Treat in Multiple Sclerosis Clinical Trials

  • AuthorsĀ  Ā : Okwuokenye, M., Zhang, A., Pace, A., Peace, K.E.
  • JournalĀ  Ā  :Neurology and Therapy
  • YearĀ  Ā  Ā  Ā  Ā :2017

Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis

  • AuthorsĀ  Ā : Fox, R.J., Chan, A., Zhang, A., … Edwards, M.R., Marantz, J.L
  • JournalĀ  Ā  :Current Medical Research and Opinion
  • YearĀ  Ā  Ā  Ā  Ā :2017

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsingā€“Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies

  • AuthorsĀ  Ā :Gold, R., Giovannoni, G., Phillips, J.T., … Zhang, A., Marantz, J.L.
  • JournalĀ  Ā  :Neurology and Therapy
  • YearĀ  Ā  Ā  Ā  Ā :2016

Comparative efficacy of first-line natalizumab vs IFN-Ī² or glatiramer acetate in relapsing MS

  • AuthorsĀ  Ā :Spelman, T., Kalincik, T., Jokubaitis, V., … Trojano, M., Butzkueven, H.
  • JournalĀ  Ā  :Neurology: Clinical Practice
  • YearĀ  Ā  Ā  Ā  Ā :2016